Welcome to our dedicated page for Alps Group SEC filings (Ticker: ALPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alps Group Inc filings document the company's foreign private issuer current-report disclosures following its completed SPAC business combination and public-company transition. Form 6-K reports furnish material-event updates, press releases, governance changes, board appointments, committee service, executive leadership appointments, employment agreement terms, capital-structure matters, and security-structure disclosures.
The filing record also covers company-specific biotechnology disclosures, including peer-reviewed case reports involving autologous Natural Killer cell infusions produced with an in-house culture protocol and CELESOME(+) exosome-related development activities. These documents frame Alps Group's formal disclosures around clinical-program communications, corporate governance, material agreements, and operating and financial reporting categories.
Alps Group Inc, an integrated biotechnology platform headquartered in Malaysia, reported fiscal year 2026 revenue of $4.9 million, up 44% year over year, driven by cellular therapy, medical testing, aesthetics services and healthcare products. Gross profit rose to $1.6 million, while gross margin declined to 32% from 39% as aesthetics services with profit-sharing and a changed revenue mix increased cost of sales.
The company recorded a net loss of $2.1 million, with basic and diluted loss per share of $(0.02) for both 2026 and 2025. Administrative expenses increased to $3.5 million, including $1,155,458 of professional fees related to its Business Combination and Nasdaq listing. Other operating income expanded to $1.3 million. Net cash used in operating activities was $2.6 million, partly offset by $2.9 million of cash from financing, leaving cash and cash equivalents of $0.6 million at March 31, 2026.
Alps highlighted completing its Business Combination with Globalink and starting to trade on Nasdaq under “ALPS,” advancing its MyImmune NK cell therapy and exosome programs, expanding MyGenome’s accreditation for whole genome sequencing under MS ISO 15189:2022, and collaborating to build a patient-derived organoid platform in Malaysia.
Alps Group Inc, a Cayman Islands holding company focused on biotechnology, reports for the fiscal year ended March 31, 2026 that it operates through Alps Life Sciences Inc and Alps Global Holding Berhad in Malaysia. Following a Business Combination with Globalink completed on October 28, 2025, its Ordinary Shares trade on Nasdaq under ALPS and its Warrants trade on OTCID under ALPWF. As of March 31, 2026 it had 166,400,314 Ordinary Shares, par value $0.0001 per share, issued and outstanding.
The company describes itself as an early-stage biotechnology business with a preclinical pipeline of biologics and biopharmaceuticals, including the MyImmune and MyCelEst platforms, with no product candidates yet in clinical trials or approved. It expects to incur significant research and development and public-company costs and states it will need substantial additional funding from equity, debt or strategic collaborations. Total liabilities were $10,199,391 as at March 31, 2026, and the company highlights risks if it cannot meet near-term obligations or raise capital, including delaying, reducing or discontinuing development programs.
Alps discloses a material weakness in internal control over financial reporting related to limited technical accounting resources and inconsistent processes, which it is attempting to remediate through enhanced controls, additional training and the appointment of a Chief Financial Officer. It also outlines extensive risks around third-party manufacturing and testing, compassionate use and medical-malpractice exposure in Malaysia, dependence on licensed and jointly owned intellectual property (including patents registered in China and a provisionally rejected ALPS trademark application in Malaysia), and the cost, complexity and uncertainty of advancing cell-based therapies from preclinical development through regulatory approval and commercialization.
Alps Group Inc, a Malaysia-based biotechnology company, is expanding into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Dr. Kong Wai Mun of Axiocell Biotech. The company is launching an internal PDO program focused on personalized cancer treatment and preclinical drug screening.
Alps aims to build Malaysia’s first clinically validated PDO platform, pursue MREC ethics approval and Medical Device Authority registration, and create a national PDO biobank to support pharmaceutical and CRO partners. The program targets major oncology centers in Malaysia, where about 51,650 new cancer cases are recorded annually and most are diagnosed at advanced stages.
Alps Group Inc reports that its subsidiary MyGenome Sdn. Bhd. has expanded its accreditation to cover Whole Genome Sequencing (WGS) under MS ISO 15189:2022, an internationally recognized clinical standard for medical laboratories.
This accreditation means MyGenome’s WGS data meets strict requirements for accuracy, reproducibility, and reliability suitable for clinical use and research programs. It places MyGenome among a limited number of Southeast Asian labs offering WGS at this standard and is intended to support adoption by hospitals, research institutions, government-linked healthcare programs, and institutional partners across the region.
Alps Group Inc received a Nasdaq notice that it is not in compliance with the exchange’s minimum bid price rule, which requires a closing bid of at least $1.00 per share for its ordinary shares. The shares traded below this level for 30 consecutive business days.
The notice does not immediately affect listing, trading, operations, or financial condition. Alps Group has 180 calendar days, until November 11, 2026, to regain compliance and may qualify for an additional 180 days if certain listing standards are met. The company is evaluating options, including a potential reverse stock split, but there is no assurance it will regain compliance, and the shares could ultimately face delisting if it cannot cure the deficiency.
Alps Group Inc director Lee Hee Hang has filed an initial ownership report showing a holding of 20,000 Ordinary Shares. The filing is a Form 3, which establishes Lee’s starting equity position in the company and does not disclose any recent share purchases or sales.
Alps Group Inc has appointed Mr. Hee H. Lee to its Board of Directors, effective April 17, 2026, expanding the Board from five to six members. He is considered independent under Nasdaq rules and is expected to join both the Audit Committee and the Compensation Committee.
Mr. Lee is a New York-licensed Certified Public Accountant with more than three decades of public accounting and advisory experience, including as a Partner at Ernst & Young LLP and long-standing advisory work with the International Swaps and Derivatives Association. The company operates an integrated biotechnology and healthcare platform focused on predictive, preventive, and precision medicine.
Alps Group Inc officer Poh Chit Laa has filed an initial statement of beneficial ownership. The filing shows direct ownership of 2,000 Ordinary Shares as of March 18, 2026. This Form 3 does not report any recent purchase, sale, or option exercise, only the existing share position.
Alps Group Inc director Chua Boon Ping filed an initial ownership report showing a direct holding of 150,000 Ordinary Shares. This Form 3 does not record a new purchase or sale but establishes the director’s existing equity stake and confirms direct ownership of these shares.
Alps Group Inc director Chew Yoke Ling has filed an initial ownership report showing a substantial equity stake in the company. The Form 3 discloses direct ownership of 6,882,720 Ordinary Shares as of the reported date. This filing records existing holdings and does not reflect any new buy or sell transaction.